Latest Dana-Farber Cancer Institute Stories
The most comprehensive search to date of DNA abnormalities in chronic lymphocytic leukemia (CLL) has unearthed several new altered genes that drive this common blood cancer, a finding that could potentially help doctors predict whether an individual patient's disease will progress rapidly or remain indolent for years.
Cancer of the liver – rare in the United States but the third-leading cause of cancer death worldwide – can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.
Hormone-blocking therapy for prostate cancer doesn't raise the risk of fatal heart attacks – as some recent studies had suggested.
In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients.
Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.
A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred.
Boston-based Internet stationery company, LookLoveSend, LLC is partnering with Dana-Farber Cancer Institute and the Jimmy Fund this holiday season to offer online access to high-quality printed,
- In medieval musical notation, a sign or neume denoting a shake or trill.